Apyx Medical Stock Earnings Reports

Apyx reported a strong Q1 2026: total revenue rose 32% YoY to $12.5M driven by a 36% increase in Surgical Aesthetics sales to $10.7M, largely from the commercial ramp of the AYON body-contouring platform, higher single-use handpiece volume and increased international generator sales. Gross margin expanded to 63.5% and adjusted EBITDA loss narrowed materially to $0.3M. Operating expenses were roughly flat; GAAP net loss improved to $2.1M ($0.05/sh). Management expects FDA 510(k) clearance for AYON power-assisted liposuction this quarter and plans a limited, disciplined early-adopter rollout when cleared. International traction is building (notably South Korea) and AYON registration efforts are underway in other key markets. Guidance was raised: 2026 revenue now $59M–$60M (Surgical Aesthetics $54M–$55M; OEM ~$5M), with expected full-year gross margin ~62%–63% and operating expenses not to exceed $45M. Cash and equivalents were $31.1M at quarter end and management projects runway through 2027 given current plans and cost discipline. Management views AYON adoption as early-stage and sees a structural tailwind from increasing GLP-1 use leading to greater demand for body-contouring procedures. Risks noted include tariffs, geographic and product mix, and the usual execution/regulatory uncertainties.